Stockscreener 앱 받기
136.30
3.49%
4.60
시장 영업 전:
138.21
1.91
+1.40%
전일 마감가:
$131.70
열려 있는:
$131.76
하루 거래량:
7.75M
Relative Volume:
1.08
시가총액:
$169.23B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
18.55
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
+1.08%
1개월 성능:
+7.13%
6개월 성능:
+9.12%
1년 성능:
+24.08%
1일 변동 폭
$131.31
$136.44
1주일 범위
$127.94
$136.44
52주 변동 폭
$107.75
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
136.30 | 169.23B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,169.17 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
249.97 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.39 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.63 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.73 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences stock trades steadily as oncology progress and HIV franchise support valuation - ad-hoc-news.de
Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences In - GuruFocus
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock - Investing.com
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv - GuruFocus
Form 4 Gilead Sciences Inc For: 16 July By Investing.com - Investing.com Canada
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock - Investing.com
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan - Stock Titan
Sepideh Moafi, Harrison Ford, Niecy Nash-Betts, Laverne Cox Added to 2026 Social Impact Summit, Hosted by The Hollywood Reporter and Social Impact Fund - Yahoo
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MSN
Form 144 GILEAD SCIENCES For: 15 July By Investing.com - Investing.com Canada
Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier - Stock Titan
GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale - Stock Titan
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? - 24/7 Wall St.
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo - MSN
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences (GILD) AGM 2026 Summary - Quartr
Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong. - Yahoo Finance
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Gilead Sciences, Inc.'s Stock Price Drops to $129.83, marking a 3.72% Decline: Time to Sell or Buy? - Smartkarma
A Look at Gilead Sciences Inc (GILD) After 3.7% Decline -- GF Va - GuruFocus
Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 -- Data Talk - Moomoo
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement - TradingKey
Gilead Sciences (GILD) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Gilead Sciences (GILD) RBC Capital Markets Global Healthcare Conference 2026 Summary - Quartr
Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In - simplywall.st
Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Gilead Sciences highlights HIV and oncology pipeline as investors track long-term growth - AD HOC NEWS
Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access - Yahoo Finance
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative - Yahoo Finance
Morgan Stanley Keeps Buy Rating on Gilead (GILD) - Insider Monkey
Gilead Sciences signals steady progress as investors watch pipeline and HIV franchise - Ad-hoc-news.de
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Cuts Target Price to $166 - Moomoo
Gilead Sciences (GILD) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
The Biktarvy from Gilead SciencesHIV combo tablet grows in US use - AD HOC NEWS
Gilead Sciences Inc Stock (GILD) Closed Up by 5.35% on Jul 7: What Signal Does It Send? - TradingKey
Westwood Enhanced Income Opportunity ETF's Gilead Sciences Inc(GILD) Holding History - GuruFocus
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36 - GuruFocus
Gilead Sciences rises as analyst upgrade adds to HIV franchise momentum - Quiver Quantitative
Gilead Sciences keeps building its antiviral pipeline. The focus shifts to long-term growth and US m - AD HOC NEWS
Gilead Stock Rallies As Trodelvy Wins First-Line Cancer Nod - StocksToTrade
Truist Financial Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $156 - Moomoo
Gilead Sciences patents new TIPARP inhibitors - BioWorld News
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
자본화:
|
볼륨(24시간):